Respiratorius AB (publ) (XSAT:RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.995
+0.025 (1.27%)
At close: Dec 3, 2025
-58.44%
Market Cap15.77M
Revenue (ttm)n/a
Net Income (ttm)-7.12M
Shares Out7.90M
EPS (ttm)-1.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,594
Average Volume21,141
Open1.930
Previous Close1.970
Day's Range1.930 - 2.070
52-Week Range1.675 - 10.500
Beta1.66
RSI44.76
Earnings DateNov 11, 2025

About Respiratorius AB

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 0
Stock Exchange Spotlight Stock Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.